[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for proposed sale of Common Stock (symbol SGRY): The filing notifies a proposed sale of 20,018 common shares to be executed through J.P. Morgan Securities LLC with an aggregate market value of $473,226 and an approximate sale date of 08/11/2025 on NASDAQ. The form reports 128,209,410 shares outstanding.

The securities listed were acquired as stock grants on 06/01/2024 (4,192 shares), 06/08/2023 (4,030 shares), 03/16/2022 (3,331 shares) and 06/04/2021 (8,465 shares). The filing indicates Nothing to Report for securities sold in the past three months and includes the standard Rule 144 representation about material adverse information and trading-plan disclosures, though no plan adoption date is provided in the form.

Positive

• Compliance: The filer submitted a Rule 144 notice disclosing the proposed sale, meeting disclosure requirements.
• Clear execution path: The sale is identified to be handled by J.P. Morgan Securities LLC.
• Acquisition detail: The filing lists specific grant dates and share amounts for the securities being sold.

Negative

• Missing issuer name in the body of the form (issuer fields are blank within the provided content).
• No price per share is provided; only aggregate market value is disclosed.
• No trading-plan date is indicated in the filing to confirm any 10b5-1 plan adoption or instruction date.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice: an insider proposes selling 20,018 shares via a major broker; disclosure is complete but not materially market-moving.

The filing documents a proposed transaction through J.P. Morgan for 20,018 common shares with an aggregate value of $473,226 and reports 128,209,410 shares outstanding. Acquisition history shows the shares originated from stock grants across 2021-2024. The form states no sales in the past three months. From a market-impact perspective, the filing is a compliance disclosure that lacks indicators of material change to issuer fundamentals.

Corporate Governance Expert

TL;DR: The filer met Rule 144 disclosure requirements; documentation of grant dates and broker routing enhances transparency but provides no governance concerns.

The notice lists acquisition dates and quantities for shares to be sold and identifies the executing broker, which supports traceability of the proposed sale. The standard signature representation about absence of undisclosed material information is included, but the form does not show a 10b5-1 adoption date or similar trading-plan timestamp. Based solely on the filing, there are no governance red flags disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	20018	473226	128209410	08/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/01/2024	2023 Stock Grant	SGRY			4192	06/01/2024	n/a
Common Stock	06/08/2023	2022 Stock Grant	SGRY			4030	06/08/2023	n/a
Common Stock	03/16/2022	2021 Stock Grant	SGRY			3331	03/16/2022	n/a
Common Stock	06/04/2021	2020 Stock Grant	SGRY			8465	06/04/2021	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the SGRY Form 144 disclose?

The filing discloses a proposed sale of 20,018 common shares via J.P. Morgan Securities LLC with aggregate market value $473,226, approximate sale date 08/11/2025 on NASDAQ.

How many shares outstanding does the filing report for SGRY?

The filing reports 128,209,410 shares outstanding.

When were the shares being sold originally acquired?

The securities were acquired as stock grants on 06/04/2021 (8,465), 03/16/2022 (3,331), 06/08/2023 (4,030) and 06/01/2024 (4,192).

Were any SGRY securities sold in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the filing indicate a 10b5-1 trading plan adoption date?

No. The form includes the standard representation about trading plans but does not show a plan adoption or instruction date in the provided content.